PUBLIC COMPANY
save$STTKShattuck Labs, Inc.
$STTKAustin, TX, USupdated 21d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Preclinical1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 2 Study of SL-325 in Crohn's Disease Patients
- phase1Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
- phase1Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
- phase1Phase 1 Study of SL-325 in Healthy Volunteers
- phase1SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
- phase1Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
- phase1Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
🐶 Hiring Signal
News
- Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem FoundationShattuck Labs initiates $75M public offering: The US biotech {$STTK} is selling over 10.5 million shares for $4 apiece, and issuing pre-funded warrants for certain investors. The offering is set to…endpoints · 2mo ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that